All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche and sobi, and supported through educational grants from Bristol Myers Squibb, Incyte and Lilly. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
Visual abstract | Latest data from the FLAIR and CAPTIVATE trials, presented at EHA 2025
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
Question 1 of 1
Based on results from the phase III FLAIR trial, what would you expect the 5-year PFS rate to be for patients with previously untreated CLL who received MRD-guided duration ibrutinib + venetoclax?
A
B
C
D
The ibrutinib + venetoclax regimen has demonstrated efficacy in patients with previously untreated chronic lymphocytic leukemia (CLL).1 The multicenter, open-label, randomized, phase III FLAIR trial (ISRCTN01844152) evaluated the efficacy and safety of ibrutinib + venetoclax, with measurable residual disease (MRD)-guided duration of treatment vs continuous ibrutinib monotherapy or fludarabine, cyclophosphamide, and rituximab (FCR).1 Results from the FLAIR trial were previously reported by the Lymphoma Hub. The phase II CAPTIVATE trial (NCT02910583) evaluated fixed-duration ibrutinib + venetoclax in patients with CLL.2 The Lymphoma Hub previously covered the 5.5 year updated results from the CAPTIVATE trial.
During the European Hematology Association (EHA) 2025 Congress, updated results from the FLAIR trial were presented by Talha Munir,1 and the final analysis of the CAPTIVATE trial was presented Paolo Ghia.2 Here, we present a visual abstract summarizing the key results.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
